EMEA-002096-PIP01-16-M03
Key facts
| Invented name |
Rozlytrek
|
| Active substance |
Entrectinib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0351/2021
|
| PIP number |
EMEA-002096-PIP01-16-M03
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of all conditions induded in the category of malignant neoplasms ( except haematopoietic and lymphoid tissue neoplasms)
|
| Route(s) of administration |
|
| Contact for public enquiries |
Roche Registration GmbH
Tel. +41 6168 79411 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|